Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Wang, Shuiliang ^a,c   Huang, Jingcao ^a   Lyu, Hui ^a   Cai, Bo ^a   Yang, Xiaoping ^a   Li, Fang ^b   Tan, Jianming ^c   Edgerton, Susan M ^a   Thor, Ann D ^a   Lee, Choon Kee ^a   Liu, Bolin ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MM 121; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; SURVIVIN; TRASTUZUMAB; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MM-121; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CELL SURVIVAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; PACLITAXEL; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886436005     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3563     Document Type: Article

References (45)

1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
2. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21:177-184. 10.1016/j.ceb.2008.12.010, 19208461.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
4. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989, 49:7147-7152.
5. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19:6115-6121. 10.1038/sj.onc.1203972, 11156524.
6. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011, 55:685-696. 10.1387/ijdb.113396se, 22161825.
7. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med 2004, 128:974-979.
8. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765. 10.1002/ijc.11273, 12866037.
9. DeFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000, 87:487-498. 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J, 10918187.
10. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006, 16:443-452. 10.1016/j.tcb.2006.07.003, 16879967.
11. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65. 10.1016/S0014-4827(02)00101-5, 12648465.
12. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010, 107:7692-7697. 10.1073/pnas.1002753107, 2867849, 20351256.
13. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
14. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887. 10.1158/0008-5472.CAN-08-0380, 18632642.
15. Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res 2005, 7:R708-R718. 10.1186/bcr1281, 1242139, 16168116.
16. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999, 18:2149-2164. 10.1093/emboj/18.8.2149, 1171299, 10205169.
17. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10:1813-1821.
18. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995, 14:4267-4275. 394510, 7556068.
19. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223. 10.1007/s10911-008-9083-7, 18454306.
20. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010, 21:944-950. 10.1016/j.semcdb.2010.08.007, 2991618, 20816829.
21. Clinicaltrials.gov http://www.clinicaltrials.gov.
22. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012, 11:582-593. 10.1158/1535-7163.MCT-11-0820, 22248472.
23. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010, 70:2485-2494. 10.1158/0008-5472.CAN-09-3145, 2840205, 20215504.
24. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009, 2:ra31. 10.1126/scisignal.2000352, 19567914.
25. Freeman DJ, Selam O, James B, Ji-Rong S, Radinsky R, Hettmann T. U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN) [abstract]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics: Nov 12-16, 2011 2011, 10(Suppl 11):p152. Abstract A182.
26. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.
27. Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236. 10.1038/onc.2010.180, 20498641.
28. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010, 70:1204-1214. 10.1158/0008-5472.CAN-09-3321, 20103628.
29. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
30. Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009, 69:8403-8411. 10.1158/0008-5472.CAN-09-2146, 19826038.
31. Huang X, Wang S, Lee CK, Yang X, Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett 2011, 307:72-79. 10.1016/j.canlet.2011.03.019, 21497990.
32. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040. 10.4161/cc.8.13.8814, 19440038.
33. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005, 1:0008. 1681463, 16729043.
34. Gradishar WJ. HER2 therapy-an abundance of riches. N Engl J Med 2012, 366:176-178. 10.1056/NEJMe1113641, 22149874.
35. Clinicaltrials.gov http://www.clinicaltrials.gov/ct2/results?term=mm-121.
36. Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 1999, 5:767-774.
37. Jamis-Dow CA, Klecker RW, Sarosy G, Reed E, Collins JM. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993, 33:48-52. 10.1007/BF00686022, 7505722.
38. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996, 56:2112-2115.
39. Kimura M, Sano M, Fujimori M, Nakagomi H, Negishi T, Yanagita Y, Sato N. Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes. Anticancer Res 2008, 28:1239-1244.
40. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012, 14:120-128. 10.1007/s11912-012-0215-2, 22234703.
41. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011, 16:485-494. 10.1016/j.drudis.2011.04.001, 21511051.
42. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011, 10:35. 10.1186/1476-4598-10-35, 3083377, 21470426.
43. Sala G, Traini S, D'Egidio M, Vianale G, Rossi C, Piccolo E, Lattanzio R, Piantelli M, Tinari N, Natali PG, Muraro R, Iacobelli S. An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene 2012, 31:1275-1286. 10.1038/onc.2011.322, 21822299.
44. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003, 9:511S-515S.
45. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3 K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212. 10.1038/sj.onc.1206394, 12761490.